Trinity Biotech
TRIB
70 hedge funds and large institutions have $251M invested in Trinity Biotech in 2013 Q3 according to their latest regulatory filings, with 15 funds opening new positions, 23 increasing their positions, 24 reducing their positions, and 8 closing their positions.
88% more first-time investments, than exits
New positions opened: 15 | Existing positions closed: 8
50% more call options, than puts
Call options by funds: $614K | Put options by funds: $409K
32% more capital invested
Capital invested by funds: $191M → $251M (+$60.4M)
9% more funds holding
Funds holding: 64 → 70 (+6)
0% more funds holding in top 10
Funds holding in top 10: 4 → 4 (0)
4% less repeat investments, than reductions
Existing positions increased: 23 | Existing positions reduced: 24
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CCMLC
Cardinal Capital Management LLC (Connecticut)
Greenwich,
Connecticut
|
+$4.26M |
| 2 |
TAM
THB Asset Management
Norwalk,
Connecticut
|
+$3.4M |
| 3 |
William Blair & Company
Chicago,
Illinois
|
+$2.82M |
| 4 |
Renaissance Technologies
New York
|
+$2.01M |
| 5 |
WA
Whitebox Advisors
Minneapolis,
Minnesota
|
+$1.95M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HA
Heartland Advisors
Milwaukee,
Wisconsin
|
-$6.23M |
| 2 |
Boston Partners
Boston,
Massachusetts
|
-$2.17M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
-$2.01M |
| 4 |
UCFA
United Capital Financial Advisors
Irving,
Texas
|
-$1.88M |
| 5 |
CCM
Corsair Capital Management
New York
|
-$1.64M |
TRIB Hedge Fund Activity: Q3 2013 in Review
70 of the 3,084 institutional investors tracked by Wall St. Rank reported a position in Trinity Biotech (TRIB) for Q3 2013, worth a combined $251M — up 32% from $191M a quarter earlier.
Buyers outnumbered sellers: 15 funds opened new TRIB positions and 8 closed out — a net gain of 7 holders — while 23 added to existing stakes and 24 trimmed.
The largest buyer was Cardinal Capital Management LLC (Connecticut), adding an estimated $4.26M. The largest seller was Heartland Advisors, cutting an estimated $6.23M.
- 70 institutional investors held Trinity Biotech (TRIB) as of Q3 2013, up from 64 in Q2 2013.
- Funds reported $251M of Trinity Biotech stock for Q3 2013, up 32% quarter-over-quarter.
- 15 funds opened new Trinity Biotech positions in Q3 2013 and 8 closed out, a net change of +7 holders.
- The largest Trinity Biotech buyer in Q3 2013 was Cardinal Capital Management LLC (Connecticut), an estimated $4.26M added.
- The largest Trinity Biotech seller in Q3 2013 was Heartland Advisors, an estimated $6.23M sold.
Based on aggregated 13F filings for Q3 2013.